Entries by oslocancer

Biotech Embrace IT Knowledge

— We have succeeded in bringing more IT knowledge to the Biotech world, says Project Manager of PERMIDES D.B.R.K. Gupta Udatha.   Merging IT and Biotech Together with five European clusters, Oslo Cancer Cluster have been managing a Horizon 2020 EU project “PERMIDES”. The cluster-to-cluster projects main goal was to stimulate collaboration between biotech companies […]

Welcome to Our New Members

Entering 2018, Oslo Cancer Cluster welcomes four new members to the fold. Cellmover, Bryn Aarflot, Kuehne + Nagel and Mercuri Urval are our new cluster members.   The Importance of Getting There Founded in 1890, Kuehne + Nagel operates from 9 locations in Norway, offering tailored logistics solutions for different industries, including for healthcare and […]

Need Money For Your Life Science Start-up?

Inven2 are distributing start-up funds in Life Science! Very good news for Biotechs and cancer research companies in their early stages of development.   Attention all Oslo Cancer Cluster and Incubator members.  Inven2 received in late December 5 million NOK from Innovation Norway. They are now, subsequently, handing them out to Life science start-ups. Inven2 […]

10th Cancer Crosslinks: Precision Treatment Reviewed

For the tenth time the cancer experts gathered to share knowledge and ideas at Oslo Cancer Cluster Innovation Park. Cancer Crosslinks 2018 presented a diverse program covering themes from immuno-oncology to cachexia, to big data.   Cancer research is changing rapidly. Immunotherapy and precision medicine has revolutionized cancer treatment. This year’s Cancer Crosslinks took a […]

Follow the 10th Cancer Crosslinks: Stream and Program

Thursday January the 18th it’s time for the 10th Cancer Crosslinks here at Oslo Cancer Cluster Innovation Park. Hospital personnel, researchers and everybody interested get together for an update on – and to discuss – the latest within cancer research.   This year’s conference will focus on Precision Treatment in cancer research with the headline: […]

Curida Takover Secures Norwegian Production

To secure Norwegian pharmaceutical production, Oslo Cancer Cluster- member Curida has completed a takeover of Ås produksjonslab AS.   Continued Production at Ås Curida operate in an international marketplace and here the last line of production of pharmaceuticals is mostly taken care of by specialized operators. «Ås produksjonslab» is a company rich in tradition, it […]

Fremtidens kreftbehandling – ta med egne data!

Les kronikken, fra 21.12. 2017 i Aftenposten, om hvordan vi bør forme våre nye sykehusbygg av Ketil Widerberg. Den nye klinikken på Radiumhospitalet må ta helsedatarevolusjonen på alvor. Radiumhospitalet ved Oslo universitetssykehus får nytt klinikkbygg. En god nyhet for kreftpasienter, som blir enda bedre hvis pasientene selv får bidra med data om egen helse. Et […]

Breakthrough Agreement for Phoenix Solutions

A new exciting collaboration among two Oslo Cancer Cluster members has been initiated. GE Healthcare has agreed to be the manufacturer of the target drug delivery platform ACT, made by Phoenix Solutions. Early Christmas Present As an early Christmas present to each other the two companies announced that they had signed an agreement securing manufacturing […]

Oncoinvent With New Lab and Bright Future

The cancer research company and Oslo Cancer Cluster-member Oncoinvent opened this Thursday a brand-new lab and research facilities at Nydalen Oslo. Now they control the whole production line and continue their development of their lead product candidate Radspherin. A Good Year 2017 has been a good year for Oncoinvent. The company has now relocated and […]

Four Cluster Companies Get Innovation Reward

Nacamed, Phoenix Soulutions, NorGenoTech and Clever Health are awarded Innovasjonsrammen for good early-stage innovation and collaboration. Innovasjonsrammen is awarded by Oslo Cancer Cluster with money from Innovation Norway. Congratulations! Important with early financing Early financing while companies are establishing their business is often limited, but can be crucial to get important projects off the ground. […]